Brussels/ Nantes, 7pm, November 7, 2007
Today the Eurofins Group celebrates its 10-year anniversary as a quoted company on Euronext as well as 20 years since its inception.
Supported initially by the city and chamber of commerce of Nantes, by local and regional government and subsequently by French agencies, universities and the European Union, Eurofins has expanded from 12 employees in 1987 to over 7,000 today in more than 100 laboratories across 27 countries around the world. The Group now provides testing and advisory services to over 20,000 customers in the food, pharmaceutical and environmental sectors.
Eurofins has recently been identified as one of the best-performing shares in Europe over the last 10 years. In a study into the extent of shareholder value creation in the German and other main European stock markets by Professor Wolfgang Gerke*, Eurofins ranks number 1 in two out of the three markets analysed in terms of value creation (Germany and the UK) and comes second when compared to French listed companies, with an annualised total shareholder return (±TSR’) of 41.79% (Oct. 1997 to September 2007).
Since the end of September, Eurofins’ share price has risen again leading to a current market capitalisation of over ¤1bn. Shareholders have thus benefited from a growth in the share price of 3,850% in the 10 years since IPO on 24th October 1997.
Operationally, Eurofins Optimed has recently won an outsourcing contract worth approximately ¤3m per year in Lyon, supporting phase 1 clinical studies in the main hospital of the city and acquiring the assets of the association for Therapeutic Research (ART).
In addition, in the USA Eurofins Medinet was awarded a seven year National Institute of Health contract worth US$ 3.4 million to manage the Network on Antimicrobial Resistance in Staphylococcus Aureus (NARSA). It will also continue to work with the National Institute of Allergy and Infectious Diseases.
On the occasion of Eurofins’ 20th anniversary Dr Gilles Martin, Eurofins founder and CEO said “Thanks to the trust and support of all our employees, customers and shareholders Eurofins has been able to reach a leading global position in the bioanalytical testing markets. Although food, pharmaceuticals and the environment have never been better tested, there remain outstanding growth opportunities in Europe and North America. In addition the world’s fastest growing economies have currently limited laboratory capacity. Eurofins has now reached a size where it is in a position to continue the deployment of a global laboratory infrastructure that will contribute to consumer and brand protection in these countries. We are thus looking forward to many years of rapid growth.”
Detailed information on Professor Gerke’s report on value creation and anniversary celebrations can be found on our website at http://www.eurofins.com.
- Value Creation from a Shareholder’s Perspective: ±The Big Picture’. October 2007
For further information about Eurofins please visit www.eurofins.com or contact: Investor Relations Phone: +32-2-769 7383 E-mail: firstname.lastname@example.org
Notes for the editor: Eurofins - a global leader in bio-analysis Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 7,000 staff in more than 100 laboratories across 27 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|EUROFINS SCIENTIF||Euronext Paris||532.70 (c)||0.29%||20 521|